2 results
Not approvedWill not start
The primary objective of this study is to evaluate the proportion of patients achieving FXI inhibition * 80% at trough (Day 91) after monthly dosing at 3 dose levels of MAA868.
Approved WMORecruiting
The purpose of this trial is to determine the safety and efficacy of TAVR via a transfemoral approach in HF patients with moderate AS as compared with OHFT with regard to the composite of death, stroke, hospital admissions, symptoms, functional…